美多芭加用吡贝地尔治疗帕金森病的临床疗效观察

Clinical Effect Assessment of Madopa with Piribedil Pakinson's Disease

目的评定美多芭与吡贝地尔联合应用治疗帕金森病的临床疗效。方法56例帕金森病病人随机分为两组,单用美多芭组(28例)和美多芭加用吡贝地尔组(28例),临床疗效采用改良Webester量表进行治疗前后评定,同时测定出现运动并发症(运动症状波动及异动症)的时间。结果临床总有效率单用美多芭组为71.43%,美多芭加用吡贝地尔组为85.71%,美多芭加用吡贝地尔组总有效率明显高于单用美多芭组(P<0.05)。单用美多芭组出现运动并发症的时间是4.02年±1.96年,美多芭加用吡贝地尔组为5.01年±2.03年,两组出现运动并发症的时间经统计学分析,差异无统计学意义(P>0.05)。结论单用美多芭和美多芭加用吡贝地尔治疗帕金森病均有效,而且美多芭加用吡贝地尔比单用美多芭治疗帕金森病有效率更高。

Objective To assess the clinical effect of Madopa in conjunction with Piribedil （P） Pakinson＇s disease （PD）. Methods Fifty-six PD patients（pts） were randomly divided into Madopa group of （ n = 28） and Madopa ＋ P group （ n = 28）, The clinical effect was assessed with modified Webster chart before and after treatment, and the occurring time of motor complications （Motor Fluctuations and Dyskinesia） was observed simultaneously. Results The total clinical effectiveness was： 74.6% for Madopa group and 86.2% for Madopa： ＋ P group, the difference between two groups was significant （P〈0.05）. The occurring time of motor complications in Madopa group was （4.02±1.96） years and that in Madopa ＋ P group was （5.01±2.03） years, the difference was not statistically significant （P〉 0.05）. Conclusion It was effective to treat PD with Madopa alone or Madopa ＋ P, the effectiveness was higher when treat with Madopa＋ P than Madppa alone.